DGCI approves anti-viral drug ‘Virafin’s emergency use for treating Covid-19

0 22

The Drugs Controller General of India (DGCI) has approved Zydus Cadila’s ‘Virafin’, an anti-viral drug for emergency use for treating COVID-19 patients. However, the same is to be used only on adults patients with moderate infection.

A single-dose subcutaneous regimen of ‘Virafin’ makes it more easy to fight the dreaded coronavirus, says researchers.

Manufactures claims that a single dose of ‘Virafin’ significantly reduces the hours of supplemental oxygen in moderate COVID-19 cases in adults. And according to trials, 91.15% of Covid-19 patients became RT-PCR negative within seven days.

With the DGCI’s approval, the ‘Virafin’ manufactures, Zydus Cadila’s shares had jumped over 4 percent. The managing director of Zydus Cadila’s informed that the life saving drug will be available in the medical market in a few days time.

Leave A Reply

Your email address will not be published.